Search research articles
Contact Us
Filters
Showing results (171-180 of 187) with videos related to
Page
of 19
Sort By:
Proceedings of the National Academy of Sciences of the United States of America
|
May 30, 2025
CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis
Sophia M Lamperis, Kaylin M McMahon, Andrea E Calvert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A Matulonis, Julie Lee, Brian Lasonde, et al.
Gynecologic Oncology
|
December 14, 2021
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study
Ursula A Matulonis, Helen Q Huang, Virginia L Filiaci, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
The New England Journal of Medicine
|
June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
March 7, 2025
Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells
Yinu Wang, Jane Frederick, Karla Isabel Medina, et al.
Gynecologic Oncology
|
June 9, 2015
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Anirban K Mitra, David A Davis, Sunil Tomar, et al.
Gynecologic Oncology
|
January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
Michael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Page
of 19
Search research articles
Search
Showing results (171-180 of 187) with videos related to
Sort By:
Page
of 19
Proceedings of the National Academy of Sciences of the United States of America
|
May 30, 2025
CRISPR screen reveals a simultaneous targeted mechanism to reduce cancer cell selenium and increase lipid oxidation to induce ferroptosis
Sophia M Lamperis, Kaylin M McMahon, Andrea E Calvert, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 28, 2012
ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer
Ursula A Matulonis, Julie Lee, Brian Lasonde, et al.
Gynecologic Oncology
|
December 14, 2021
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study
Ursula A Matulonis, Helen Q Huang, Virginia L Filiaci, et al.
British Journal of Cancer
|
October 25, 2018
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
Michael Friedlander, Ursula Matulonis, Charlie Gourley, et al.
The New England Journal of Medicine
|
June 13, 2019
Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer
Daniela Matei, Virginia Filiaci, Marcus E Randall, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
March 7, 2025
Chromatin Organization Governs Transcriptional Response and Plasticity of Cancer Stem Cells
Yinu Wang, Jane Frederick, Karla Isabel Medina, et al.
Gynecologic Oncology
|
June 9, 2015
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Anirban K Mitra, David A Davis, Sunil Tomar, et al.
Gynecologic Oncology
|
January 24, 2025
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258
Aine Clements, Danielle Enserro, Kyle C Strickland, et al.
British Journal of Cancer
|
April 8, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 10, 2006
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status
Michael S Gordon, Daniela Matei, Carol Aghajanian, et al.
Page
of 19